These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7666077)

  • 21. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.
    Small EJ; Meyer M; Marshall ME; Reyno LM; Meyers FJ; Natale RB; Lenehan PF; Chen L; Slichenmyer WJ; Eisenberger M
    J Clin Oncol; 2000 Apr; 18(7):1440-50. PubMed ID: 10735891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
    Bowden CJ; Figg WD; Dawson NA; Sartor O; Bitton RJ; Weinberger MS; Headlee D; Reed E; Myers CE; Cooper MR
    Cancer Chemother Pharmacol; 1996; 39(1-2):1-8. PubMed ID: 8995493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer.
    Tu SM; Pagliaro LC; Banks ME; Amato RJ; Millikan RE; Bugazia NA; Madden T; Newman RA; Logothetis CJ
    Clin Cancer Res; 1998 May; 4(5):1193-201. PubMed ID: 9607577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suramin: rapid loading and weekly maintenance regimens for cancer patients.
    van Rijswijk RE; van Loenen AC; Wagstaff J; Meijer E; Lopez R; van Groeningen CJ; Heimans JJ; Pinedo HM
    J Clin Oncol; 1992 Nov; 10(11):1788-94. PubMed ID: 1403059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.
    Myers C; Cooper M; Stein C; LaRocca R; Walther MM; Weiss G; Choyke P; Dawson N; Steinberg S; Uhrich MM
    J Clin Oncol; 1992 Jun; 10(6):881-9. PubMed ID: 1375283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
    Hudes GR; Nathan F; Khater C; Haas N; Cornfield M; Giantonio B; Greenberg R; Gomella L; Litwin S; Ross E; Roethke S; McAleer C
    J Clin Oncol; 1997 Sep; 15(9):3156-63. PubMed ID: 9294479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
    Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
    Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.
    Small EJ; McMillan A; Meyer M; Chen L; Slichenmyer WJ; Lenehan PF; Eisenberger M
    J Clin Oncol; 2001 Mar; 19(5):1304-11. PubMed ID: 11230472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.
    Westermann AM; Dubbelman R; Baars JP; Moolenaar WH; Beijnen JH; Rodenhuis S
    Cancer Chemother Pharmacol; 2000; 46(1):57-62. PubMed ID: 10912579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
    Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
    Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
    Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adaptive control with feedback strategies for suramin dosing.
    Cooper MR; Lieberman R; La Rocca RV; Gernt PR; Weinberger MS; Headlee DJ; Kohler DR; Goldspiel BR; Peck CC; Myers CE
    Clin Pharmacol Ther; 1992 Jul; 52(1):11-23. PubMed ID: 1623689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of suramin in patients with metastatic renal cell carcinoma.
    Dreicer R; Smith DC; Williams RD; See WA
    Invest New Drugs; 1999; 17(2):183-6. PubMed ID: 10638490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
    Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
    J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suramin treatment in hormone- and chemotherapy-refractory prostate cancer.
    Garcia-Schürmann JM; Schulze H; Haupt G; Pastor J; Allolio B; Senge T
    Urology; 1999 Mar; 53(3):535-41. PubMed ID: 10096380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
    Lara PN; Stadler WM; Longmate J; Quinn DI; Wexler J; Van Loan M; Twardowski P; Gumerlock PH; Vogelzang NJ; Vokes EE; Lenz HJ; Doroshow JH; Gandara DR
    Clin Cancer Res; 2006 Mar; 12(5):1556-63. PubMed ID: 16533781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of adaptive control with feedback to individualize suramin dosing.
    Scher HI; Jodrell DI; Iversen JM; Curley T; Tong W; Egorin MJ; Forrest A
    Cancer Res; 1992 Jan; 52(1):64-70. PubMed ID: 1727387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective study of suramin-induced peripheral neuropathy.
    Chaudhry V; Eisenberger MA; Sinibaldi VJ; Sheikh K; Griffin JW; Cornblath DR
    Brain; 1996 Dec; 119 ( Pt 6)():2039-52. PubMed ID: 9010008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
    Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
    J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.
    Savarese DM; Halabi S; Hars V; Akerley WL; Taplin ME; Godley PA; Hussain A; Small EJ; Vogelzang NJ
    J Clin Oncol; 2001 May; 19(9):2509-16. PubMed ID: 11331330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.